secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001104659-25-023218
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone reports Q4 2024 net loss $12.4M; FDA PDUFA date for CARDAMYST is March 27, 2025
--------------------------------------------------------------------------------

- FDA PDUFA goal date for CARDAMYST (etripamil) in PSVT is March 27, 2025; launch targeted for mid-2025 if approved.
- Cash, cash equivalents, and short-term investments: $69.7M as of Dec 31, 2024, vs $66.0M year-end 2023.
- Q4 2024 net loss $12.4M ($0.19/share), improved from $13.6M ($0.32/share) in Q4 2023.
- Full year 2024 net loss $41.5M ($0.67/share), vs $59.7M ($1.39/share) in 2023; revenue zero.
- Phase 3 trial for etripamil in AFib-RVR on track to initiate in 2025 with patient self-administration regimen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/0001104659-25-023218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-023218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer